Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 2/20 | 0.40 |
| ▸ | BCR | P11274 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806421 | 0.87 | HSP90AA1 (0.49) | HSP90AA1POLBALDH1A1PTPN11HSP90AB1 | |
| SCHEMBL2806500 | 0.85 | HSP90AA1 (0.52) | HSP90AA1POLBALDH1A1HSP90AB1MAPT | |
| SCHEMBL8195614 | 0.85 | HSP90AA1 (0.51) | HSP90AA1POLBALDH1A1PTPN11KDM4E | |
| SCHEMBL17624125 | 0.79 | HSP90AB1 (0.50) | HSP90AA1POLBALDH1A1KDM4EHSP90AB1 | |
| SCHEMBL8203593 | 0.78 | ALDH1A1 (0.45) | POLBALDH1A1KDM4EKMT2AMAPT | |
| SCHEMBL8195601 | 0.76 | KMO (0.51) | POLBALDH1A1KDM4EMAPT | |
| SCHEMBL1017921 | 0.75 | MAPT (0.77) | HSP90AA1HSP90AB1MAPT | |
| SCHEMBL13223161 | 0.74 | HSP90AA1 (0.41) | HSP90AA1POLBALDH1A1KDM4EHSP90AB1 | |
| SCHEMBL19498179 | 0.74 | HSP90AB1 (0.47) | HSP90AA1POLBALDH1A1KDM4EHSP90AB1 | |
| SCHEMBL19504884 | 0.74 | HSP90AB1 (0.55) | HSP90AA1POLBALDH1A1KDM4EHSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | NOVARTIS AG (CH) | 2010-09-23 | — | — | US | disclosed |
| WO-2008033389-A2 | MACROCYCLIC HCV INHIBITORS AND THEIR USES | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240638-A1 | Organic Compounds and their uses | OAT, HAVCR2, CYP3A43 | HSP90AA1 2838/4885POLB 1368/4885ALDH1A1 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.